G1 Therapeutics Inc (NASDAQ:GTHX)’s share price traded down 15.5% on Monday . The stock traded as low as $39.30 and last traded at $39.54. 692,603 shares were traded during trading, an increase of 145% from the average session volume of 282,310 shares. The stock had previously closed at $46.81.
Several equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $79.00 price objective on shares of G1 Therapeutics in a research note on Monday, September 17th. Needham & Company LLC raised their price objective on G1 Therapeutics to $76.00 and gave the company a “buy” rating in a research note on Tuesday, September 18th. BidaskClub cut G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 19th. BTIG Research assumed coverage on G1 Therapeutics in a research note on Monday, September 10th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Cowen restated a “buy” rating on shares of G1 Therapeutics in a research note on Thursday, August 9th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $74.50.
The stock has a market cap of $1.56 billion, a PE ratio of -11.08 and a beta of -1.02.
G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Wednesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.01. Research analysts predict that G1 Therapeutics Inc will post -2.66 EPS for the current fiscal year.
In other news, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $50.79, for a total transaction of $38,092.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jay Strum sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $59.60, for a total value of $596,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 66,583 shares of company stock valued at $3,614,546. Insiders own 15.92% of the company’s stock.
Several institutional investors have recently made changes to their positions in GTHX. Cubist Systematic Strategies LLC boosted its stake in G1 Therapeutics by 484.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock worth $104,000 after purchasing an additional 2,316 shares during the period. BNP Paribas Arbitrage SA boosted its stake in G1 Therapeutics by 58.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock worth $105,000 after purchasing an additional 1,045 shares during the period. Great West Life Assurance Co. Can boosted its stake in G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock worth $113,000 after purchasing an additional 1,560 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in G1 Therapeutics by 44.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock worth $144,000 after purchasing an additional 1,200 shares during the period. Finally, Strs Ohio boosted its stake in G1 Therapeutics by 78.3% in the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock worth $178,000 after purchasing an additional 1,800 shares during the period. 69.17% of the stock is owned by hedge funds and other institutional investors.
About G1 Therapeutics (NASDAQ:GTHX)
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
See Also: What is insider trading?
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.